Patents by Inventor Stephen Pelly

Stephen Pelly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pan-Tropic Entry Inhibitors
    Publication number: 20230271961
    Abstract: This disclsore relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.
    Type: Application
    Filed: April 10, 2023
    Publication date: August 31, 2023
    Inventors: Dennis Liotta, Edgars Jecs, Yesim Altas Tahirovic, Lawrence Wilson, Stephen Pelly
  • Pan-tropic entry inhibitors
    Patent number: 11649235
    Abstract: This disclosure relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 16, 2023
    Assignee: Emory University
    Inventors: Dennis Liotta, Edgars Jecs, Yesim Altas Tahirovic, Lawrence Wilson, Stephen Pelly
  • INHIBITORS OF RSV REPLICATION AND APPLICATIONS THEREOF
    Publication number: 20210244740
    Abstract: Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as well as compounds targeting Px. The compounds can be used to treat patients with RSV infection.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 12, 2021
    Inventors: Richard PLEMPER, Julien SOURIMANT, Edgars JECS, Dennis LIOTTA, Stephen PELLY, Robert WILSON, Zackery Will DENTMON
  • Pan-Tropic Entry nhibitors
    Publication number: 20210017178
    Abstract: This disclosure relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.
    Type: Application
    Filed: March 19, 2019
    Publication date: January 21, 2021
    Inventors: Dennis Liotta, Edgars Jecs, Yesim Altas Tahirovic, Lawrence Wilson, Stephen Pelly